Haemonetics (NYSE: HAE) reported Q4 EPS of $0.39, $0.01 better than the analyst estimate of $0.38. Revenue for the quarter came in at $228.1 million versus the consensus estimate of $219.42 million.

GUIDANCE:

Haemonetics sees FY2018 EPS of $1.55-$1.65, versus the consensus of $1.59.

For earnings history and earnings-related data on Haemonetics (HAE) click here.